3 recruiting, 2 suspended, 1 not yet recruiting. 4 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Suspended 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Recruiting 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Actinium: new trials by email Literature Review of Actinium trials Research Report on Actinium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 53 | 2026-11-18 | 2026-08-24 |
| Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab - Refractory Myelodysplastic Syndrome | Phase 1 | Suspended | National Cancer Institute (NCI) | 18 | 2026-09-03 | 2026-09-09 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
| ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium Actinium (225Ac) rhPSMA-10.1 - Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | University College, London | 60 | 2026-04-13 | 2026-05-08 |
| Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide - Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 107 | 2025-12-12 | 2026-09-17 |
Prostatic Neoplasms (2) · Glioblastoma (1) · Gliosarcoma (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1)
National Cancer Institute (NCI) (3) · AstraZeneca (1) · Jonsson Comprehensive Cancer Center (1) · University College, London (1)
United States (4) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Finland (1) · France (1) · Germany (1) · India (1) · Israel (1) · Italy (1) · Japan (1)
Amar Kishan (1) · Gerhardt Attard (1) · Manu Pandey (1) · Megan Mantica (1) · Talha Badar (1)
UM1CA186689 (1), UM1CA186690 (1), UM1CA186709 (1)